Brokers Set Expectations for CGEM Q3 Earnings

Key Points

• Analysts at HC Wainwright predict Cullinan Therapeutics will report a Q3 2025 loss of ($0.98) per share, with a full-year estimate of ($3.04) EPS and a "Buy" rating with a price target of $24.00.
• The company's recent quarterly earnings report revealed a loss of ($1.07) per share, missing the consensus estimate of ($0.83).
• Cullinan Therapeutics has a current market cap of $483.78 million and approximately 86.31% of the stock is owned by institutional investors and hedge funds.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings estimates for Cullinan Therapeutics in a research note issued on Thursday, August 21st. HC Wainwright analyst R. Burns expects that the company will earn ($0.98) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.01) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($1.15) EPS and FY2026 earnings at ($4.40) EPS.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.24).

A number of other equities analysts also recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Cullinan Therapeutics in a research note on Wednesday, June 11th. They set a "buy" rating and a $22.00 price target on the stock. UBS Group cut their price target on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Morgan Stanley cut their price target on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating on the stock in a research note on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cullinan Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $26.80.

Cullinan Therapeutics Stock Up 6.8%

NASDAQ:CGEM opened at $8.19 on Monday. The company has a market cap of $483.78 million, a P/E ratio of -2.54 and a beta of -0.08. Cullinan Therapeutics has a fifty-two week low of $6.85 and a fifty-two week high of $19.89. The firm's 50 day moving average is $7.80 and its two-hundred day moving average is $8.15.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of large investors have recently added to or reduced their stakes in CGEM. Wells Fargo & Company MN grew its holdings in Cullinan Therapeutics by 47.9% during the 4th quarter. Wells Fargo & Company MN now owns 24,864 shares of the company's stock valued at $303,000 after purchasing an additional 8,056 shares in the last quarter. Invesco Ltd. boosted its stake in Cullinan Therapeutics by 2.4% during the 4th quarter. Invesco Ltd. now owns 59,553 shares of the company's stock valued at $725,000 after acquiring an additional 1,395 shares during the last quarter. Mariner LLC boosted its stake in Cullinan Therapeutics by 125.3% during the 4th quarter. Mariner LLC now owns 34,901 shares of the company's stock valued at $425,000 after acquiring an additional 19,411 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Cullinan Therapeutics by 28.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,318,372 shares of the company's stock valued at $16,058,000 after acquiring an additional 295,467 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its stake in Cullinan Therapeutics by 7.4% during the 4th quarter. MetLife Investment Management LLC now owns 32,058 shares of the company's stock valued at $390,000 after acquiring an additional 2,217 shares during the last quarter. 86.31% of the stock is owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.